Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

NAPROXEN 375 MG TABLET

naproxen
$0.0736per EA
High Outlier

Strength

375 mg/1

Manufacturer

Cipla USA Inc.

NDC

69097085412

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

2/17/2021

Active Ingredients

NAPROXEN

Approval Type

Generic (ANDA)

FDA Application

ANDA091305

On Market Since

7/5/2016

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

+33.4%

Generic Alternatives

1 alternative • Same active ingredient

NAPROXEN 375 MG TABLET
Generic
69097085407•Cipla USA Inc.
$0.0736

Related Drugs

Same classification

MINIPRIN EC 81 MG TABLET
Generic
49483033010•Time-Cap Labs Inc.
$0.0118
per EA
MINIPRIN EC 81 MG TABLET
Generic
49483033012•Time-Cap Labs Inc.
$0.0118
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035203•Chain Drug Marketing Association
$0.0121
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035210•Chain Drug Marketing Association
$0.0121
per EA
ST. JOSEPH ASPIRIN EC 81 MG TB
Generic
69536018112•Foundation Consumer Healthcare LLC
$0.0139
per EA
ASPIRIN EC 81 MG TABLET
Generic
00536123441•Rugby Laboratories
$0.0147
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904675180•Major Pharmaceuticals
$0.0147
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904678370•Major Pharmaceuticals
$0.0147
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059848•AmerisourceBergen
$0.0147
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059887•AmerisourceBergen
$0.0147
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy